GEN-MKT-18-7897-A
Feb 15, 2018 | Blogs, Food / Beverage | 0 comments
Glyphosate is a polar pesticide widely used as a garden herbicide. It is an ingredient in the world’s bestselling weed killer, which farmers consider one of their best solutions to their super weed problems.
However, the chemical has become one of the most controversial topics as concerns about health implications increase. What’s more, lack of rigorous testing methods has also drawn criticism. Yet, regulators across seem to have differing opinions on these issues and its widely used in farming is still authorized.
Many contemporary methods fail to address reproducibility and sensitivity. Consequently, labs are seeking even more efficient and robust analytical testing methods to help identify as many polar pesticides in food, feed, and environment, within in a single analysis.
There are 2 constraints you need to know need when evaluating glyphosate testing methods:
The good news? SCIEX has teamed up with NofaLab, a Rotterdam-based contract testing laboratory to develop a non-derivatized method.
This new method, is based on ion chromatography and optimized on the SCIEX 6500+ QTRAP® LC-MS/MS System, has high sensitivity, linearity, and reproducibility for food, feed, and water samples.
Download a content pack to learn more about this robust and sensitive method and how you can stay ahead of your glyphosate analysis. The content pack includes:
As an analytical strategy, middle-down mass spectrometry (MS) workflows characterize biotherapeutic proteins by analyzing large, digested protein fragments or defined subunits, rather than fully intact proteins (top-down) or digested peptides (bottom-up). A middle-down strategy combines the strengths of top-down and bottom-up approaches by delivering high sequence coverage and structural specificity while maintaining relatively simple sample preparation. In practice, middle-down analysis enables accurate mass measurement, rapid sequence confirmation, and localization of key post-translational modifications (PTMs) on protein subunits that are directly relevant to product quality.
In biopharmaceutical development, sequence variants (SV) are considered an inherent risk of producing complex proteins in living systems. Sequence variants are unintended changes to the amino acid sequence of a biotherapeutic and can be caused by errors in transcription or translation in the host cell, or cell culture and process conditions. Detailed analysis of SVs is important in process and product development to ensure the drug’s safety and efficacy. Even low‑level sequence variants can have significant implications for product quality, safety, and efficacy, making their accurate detection and characterization a critical requirement across development, process optimization, and regulatory submission.
CE‑SDS remains a cornerstone assay for characterizing fragmentation, aggregation, and product‑related impurities in therapeutic proteins. UV detection has been the long‑standing standard. However, it frequently struggles with baseline noise, limited sensitivity for minor fragments, and subjective integration.
Posted by
You must be logged in to post a comment.
Share this post with your network